Within five years, the first hospitals should be able to completely analyse all of the proteins in a patient’s blood and urine in order to provide more individualised treatment. That is the ambition of the researchers at Utrecht University and their four European partners. The researchers have received a 3.7 million Euro grant for their MSmed research proposal as part of the Future and Emerging Technologies programme within the Horizon 2020 project. On 14 and 15 January, MSmed officially kicked off its activities at an event in Copenhagen.
ICI researcher Carl Figdor (Radboud UMC, Dept. of Tumor Immunology, theme Cancer development en immune defence) received a novel EU 2020 grant named PRECIOUS to develop biodegradable nanomedicines for multimodal precision cancer immunotherapy. In this five year program (8.3 Million Euro’s) the team will produce nanoparticles filled with compounds that manipulate the immune system and test these in the clinic.
In a paper in Chemical Science, ICI PhD student Daphne van Elsland (Leiden University) and colleagues have combined two techniques that together enable visualization of bacteria being degraded by immune cells.
Ton Schumacher (Netherlands Cancer Institute and ICI executive board member) has received the Meyenburg Award 2015 on Wednesday, September 11th.
The award is established by the German Meyenburg Foundation, which aims to stimulate excellence in cancer research. The prize is awarded annually to an internationally acclaimed scientist for his or her outstanding achievements. Schumacher receives this award in recognition of his research on T cell recognition of human cancer.
NKI researcher and ICI scientific director Sjaak Neefjes will give the Van Loghem Lecture 2015 at the annual meeting of the Dutch Society for Immunology on Wednesday December 16th, 2015. With this, Neefjes joins the rank of renowned Dutch immunologists who previously received this honor.
The American Chemical Society has honoured Albert Heck with the ‘ACS Frank H. Field and Joe L. Franklin Award for Outstanding Achievements in Mass Spectrometry’. Heck receives the award for his development of new methods and techniques to identify and study the structure and function of proteins and protein complexes.
In the field of Chemistry, the American Chemical Society Awards are considered to be very prestigious, and are almost exclusively presented to researchers from America. The Award will be presented during the meetings of the American Chemical Society in March 2016.
ICI researchers at the Netherlands Cancer Institute have discovered three new resistance mechanisms of cancer cells against the commonly used anti-cancer drugs doxorubicin and etoposide. In The Netherlands alone, thousands of patients a year are treated with one of these drugs. But they don't always work well for every patient. The new discovery might help predict whether a patient will or will not benefit from them.
Hermen Overkleeft (Leiden Institute of Chemistry, University Leiden) has been awarded the Jeremy Knowles Award 2015 for his innovative and insightful development of activity-based protein probes for the imaging and identification of enzymes in health and disease. The award of the Royal Society of Chemistry is to recognise and promote the importance of inter- and multidisciplinary research between chemistry and the life sciences.
Sjaak Neefjes, scientific director of the ICI, has been selected as one of 16 new Academy members.
Prof. Sjaak Neefjes is an internationally leading researcher in the field of cellular immunology. He investigates how cells control the immune system and how they flag up infection. He invented new techniques to visualise and manipulate reactions within cells, through which he is able to follow processes in healthy and diseased cells. He has been praised for his originality and multidisciplinary approach, and many of his inventions have already led to clinical applications.
T-Cell Factory, a Netherlands-based company specialising in the discovery, characterisation and selection of therapeutically promising T-cell receptors (TCR) will continue its activities as part of US-based Kite Pharma. TCRs have the potential to activate T-cells (the ‘killer’ cells of the body's immune system) with high specificity against tumor cells. One of the founders of T-Cell Factory is Prof. Dr. Ton Schumacher of the Netherlands Cancer Institute, who is also on the ICI Executive Board.